Combination Antitumor Activation of Anlotinib with Radiofrequency Ablation in Human Medullary Thyroid Carcinoma

Title:Combination Antitumor Activation of Anlotinib with Radiofrequency Ablation in Human Medullary Thyroid Carcinoma

Volume: 25

Author(s): Zhou Zhao, Xue Ma, Yuanmeng Li, Shi-hui Zhou, Li-E Zang, Fan Feng*Naishi Li

Affiliation:

• Department of Clinical Laboratory, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
• The Library, Shaanxi Normal University, Xi'an, 710062, PR China

Keywords: Medullary thyroid carcinoma, molecular targeted drugs, anlotinib, radiofrequency ablation, combination therapeutic strategies.

Abstract:

Introduction: Currently, Medullary Thyroid Carcinoma (MTC) is considered a kind of rare neuroendocrine tumor, and molecular-targeted drugs have previously been used for MTC treatment.

Method: However, the prognosis of MTC patients is still not significant. In the present work, we aimed to explore the antitumor activity of the molecularly targeted drug anlotinib in combination with radiofrequency ablation on MTC.

Result: The targets of anlotinib were clearly expressed in MTC tissue specimens, and the expression level of these factors was much higher in MTC clinical specimens than in nontumor tissues. At the same time, anlotinib or Radiofrequency Ablation (RFA) showed clear antitumor activity against the MTC cell line TT (TT cells) and the tumor tissue it formed. Anlotinib, in combination with RFA, significantly increased the antitumor activity of RFA.

Conclusion: These results indicated that the combination of anlotinib with radiofrequency ablation could be a promising therapeutic strategy for MTC treatment.

Cite this article as:

Zhao Zhou, Ma Xue, Li Yuanmeng, Zhou Shi-hui, Zang Li-E, Feng Fan*, Li Naishi, Combination Antitumor Activation of Anlotinib with Radiofrequency Ablation in Human Medullary Thyroid Carcinoma, Current Molecular Medicine 2025; 25 () . https://dx.doi.org/10.2174/0115665240323681241023100958